MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Revenue
$875K
Net Income
-$40,123K
Net Profit Margin
-4585.49%
EPS
-$0.95
Unit: Thousand (K) dollars
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-03-31
2025-12-31
2025-09-30
2025-06-30
Collaboration revenue
875
-7,837*
1,614
-
Research and development
33,054
24,080*
38,361
-
General and administrative
10,124
10,183*
10,304
-
Total operating expenses
43,178
34,263*
48,665
-
Loss from operations
-42,303
-42,100*
-47,051
-
Interest and other income
2,624
3,054
3,571
-
Total other income
2,624
3,054*
3,571
-
Loss before provision for income taxes
-39,679
-39,046
-43,480
-42,925
Provision for income taxes
38
118
654
178
Net loss
-39,717
-39,164
-44,134
-43,103
Unrealized (loss) gain on marketable securities
-406
31
221
-37
Total other comprehensive (loss) gain
-406
31
221
-37
Total comprehensive loss
-40,123
-39,133
-43,913
-43,140
Basic EPS
-0.95
-0.94
-1.06
-1.04
Diluted EPS
-0.95
-0.94
-1.06
-1.04
Basic Average Shares
41,836,275
41,610,893
41,462,567
41,338,752
Diluted Average Shares
41,836,275
41,610,893
41,462,567
41,338,752
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Total comprehensive
loss
-$40,123K
(-137.85%↓ Y/Y)
Net loss
-$39,717K
(-128.93%↓ Y/Y)
Total other
comprehensive (loss) gain
-$406K
(-184.58%↓ Y/Y)
Interest and other income
$2,624K
(-40.91%↓ Y/Y)
Loss before
provision for income taxes
-$39,679K
(-128.71%↓ Y/Y)
Provision for income taxes
$38K
Unrealized (loss) gain on
marketable securities
-$406K
(-184.58%↓ Y/Y)
Total other income
$2,624K
(-40.91%↓ Y/Y)
Loss from operations
-$42,303K
(-94.14%↓ Y/Y)
Collaboration revenue
$875K
(-95.74%↓ Y/Y)
Total operating
expenses
$43,178K
(1.96%↑ Y/Y)
Research and development
$33,054K
(3.06%↑ Y/Y)
General and
administrative
$10,124K
(-1.46%↓ Y/Y)
Buy us a coffee
Entrada Therapeutics, Inc. (TRDA)
Entrada Therapeutics, Inc. (TRDA)